TAK Earnings & Financial Statements
Takeda Pharmaceutical Company Limited
$19.01
+$0.49(+2.65%)
60
Overall
60
Value
63
Tech
57
Quality
Market Cap
$58.52B
Volume
4.49M
52W Range
$12.99 - $19.10
Target Price
$21.97
TAK earnings and financial statements: Takeda Pharmaceutical Company Limited's income statement, balance sheet and cash flow statement, annual and quarterly.
TAK Annual Financial Statements
| Fiscal year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Revenue | $4.51T | $4.58T | $4.26T |
| Cost of revenue | $1.57T | $1.58T | $1.43T |
| Operating income | -$18.53B | $316.38B | $420.60B |
| EBITDA | $936.34B | $1.15T | $1.00T |
| Net income | -$152.39B | $107.93B | -$38.74B |
| EPS (diluted) | $-48.38 | $16.81 | $45.58 |
| Fiscal year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total assets | $15.51T | $14.25T | $15.11T |
| Total liabilities | $8.08T | $7.31T | $7.83T |
| Shareholders’ equity | $7.43T | $6.94T | $7.27T |
| Cash and equivalents | $595.05B | $385.11B | $457.80B |
| Long-term debt | $4.37T | $3.97T | $4.48T |
| Fiscal year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Operating cash flow | $1.04T | $1.06T | $716.34B |
| Free cash flow | $630.50B | $709.34B | $235.61B |
| Dividends paid | $311.90B | $302.50B | $287.19B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TAK | $19.01 | +2.6% | 4.49M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Takeda Pharmaceutical Company Limited Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW